Larry Bell - Axcella Health Global VP
| AXLADelisted Stock | USD 0.20 0.02 11.11% |
Insider
Larry Bell is Global VP of Axcella Health
| Phone | 857 320 2200 |
| Web | https://www.axcellahealth.com |
Axcella Health Management Efficiency
The company has return on total asset (ROA) of (0.877) % which means that it has lost $0.877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.7017) %, meaning that it created substantial loss on money invested by shareholders. Axcella Health's management efficiency ratios could be used to measure how well Axcella Health manages its routine affairs as well as how well it operates its assets and liabilities.Axcella Health currently holds 2.16 M in liabilities with Debt to Equity (D/E) ratio of 3.02, implying the company greatly relies on financing operations through barrowing. Axcella Health has a current ratio of 2.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axcella Health's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Noreen MD | Kezar Life Sciences | 59 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Timothy Moore | Instil Bio | 63 | |
| Mark Peikin | Adial Pharmaceuticals | N/A | |
| Mark Dudley | Instil Bio | N/A | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Christopher Winrow | Cyclerion Therapeutics | N/A | |
| Dr IV | Assembly Biosciences | 52 | |
| Bronson Crouch | Instil Bio | 51 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Annie Mack | Akari Therapeutics PLC | N/A | |
| Anjeza Gjino | Cyclerion Therapeutics | 41 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Sumita JD | Instil Bio | 50 | |
| Nicole White | Assembly Biosciences | N/A | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Ronald CPA | RenovoRx | N/A | |
| Torsten Hombeck | Akari Therapeutics PLC | 54 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -13.7 | |||
| Return On Asset | -0.88 |
Axcella Health Leadership Team
Elected by the shareholders, the Axcella Health's board of directors comprises two types of representatives: Axcella Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axcella. The board's role is to monitor Axcella Health's management team and ensure that shareholders' interests are well served. Axcella Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axcella Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Virginia Dean, VP Officer | ||
| Dan Kirby, VP Operations | ||
| Laurent Chardonnet, Consultant | ||
| William Hinshaw, President CEO | ||
| Margaret MD, VP Officer | ||
| Paul JD, Chief VP | ||
| Alison MD, Pres Operations | ||
| Larry Bell, Global VP | ||
| Robert Crane, VP CFO |
Axcella Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axcella Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.7 | |||
| Return On Asset | -0.88 | |||
| Current Valuation | 1.94 M | |||
| Shares Outstanding | 2.95 M | |||
| Shares Owned By Insiders | 15.77 % | |||
| Shares Owned By Institutions | 66.67 % | |||
| Number Of Shares Shorted | 78.18 K | |||
| Price To Earning | (1.10) X | |||
| Price To Book | 8.74 X | |||
| EBITDA | (67.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Axcella Stock
If you are still planning to invest in Axcella Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axcella Health's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |